PCP
MRNA icon

Perbak Capital Partners’s Moderna MRNA Stock Holding History

Perbak Capital Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$558K Buy
+10,991
New +$513K 0.14% 171

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Perbak Capital Partners's MRNA Position: Q1 2026 in Review

Perbak Capital Partners opened a new position in Moderna (MRNA) in Q1 2026: 10,991 shares worth $558K. The stake represents 0.14% of the portfolio and ranks #171 among its holdings.

722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Perbak Capital Partners held 10,991 shares of Moderna worth $558K as of Q1 2026.
  • Moderna was a new Perbak Capital Partners position in Q1 2026.
  • Moderna made up 0.14% of Perbak Capital Partners's portfolio in Q1 2026, its #171 holding.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Perbak Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.